Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

Alice M. Jenh, Paul Pham

Research output: Contribution to journalArticle

Abstract

Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.

Original languageEnglish (US)
Pages (from-to)1079-1092
Number of pages14
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Tenofovir
Chronic Hepatitis B
Therapeutics
Fumarates
Reverse Transcriptase Inhibitors
Lamivudine
Prodrugs
Practice Guidelines
Nucleosides
Hepatitis B virus
Antiviral Agents
HIV-1

Keywords

  • chronic hepatitis B
  • nucleotide analog reverse transcriptase inhibitor
  • tenofovir disoproxil fumarate

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. / Jenh, Alice M.; Pham, Paul.

In: Expert Review of Anti-Infective Therapy, Vol. 8, No. 10, 10.2010, p. 1079-1092.

Research output: Contribution to journalArticle

Jenh, Alice M. ; Pham, Paul. / Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. In: Expert Review of Anti-Infective Therapy. 2010 ; Vol. 8, No. 10. pp. 1079-1092.
@article{7e4a7fc4abbf485186575f776ce717fe,
title = "Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B",
abstract = "Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.",
keywords = "chronic hepatitis B, nucleotide analog reverse transcriptase inhibitor, tenofovir disoproxil fumarate",
author = "Jenh, {Alice M.} and Paul Pham",
year = "2010",
month = "10",
doi = "10.1586/eri.10.91",
language = "English (US)",
volume = "8",
pages = "1079--1092",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

AU - Jenh, Alice M.

AU - Pham, Paul

PY - 2010/10

Y1 - 2010/10

N2 - Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.

AB - Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.

KW - chronic hepatitis B

KW - nucleotide analog reverse transcriptase inhibitor

KW - tenofovir disoproxil fumarate

UR - http://www.scopus.com/inward/record.url?scp=77958156082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958156082&partnerID=8YFLogxK

U2 - 10.1586/eri.10.91

DO - 10.1586/eri.10.91

M3 - Article

C2 - 20954872

AN - SCOPUS:77958156082

VL - 8

SP - 1079

EP - 1092

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 10

ER -